ERBB2 and breast cancer: In India, a minority (<5%) of BC patients are likely to opt for ODX testing.[7] Current clinical practice in BC employs assessment of tumor size, tumor focality, mitotic rate, tubular differentiation, nuclear morphology, tumor invasion, histologic grade, node involvement followed by hormonal, human epidermal growth factor receptor 2 (HER2), and tumor cell proliferation biomarker testing.